This review aims to provide a current understanding, and future perspectives, of Lp(a), which is currently considered a mere biomarker but may emerge as a novel therapeutic target in future clinical settings.
Introduction
Atherosclerotic cardiovascular disease (ASCVD), including coronary artery disease and stroke, is the leading cause of mortality worldwide. Despite advancements in ASCVD prevention through LDLlowering therapies, using statins and various other agents, so-called "residual risk" remains a significant challenge [1] [2] [3] . Of several biomarkers shown as residual risks, lipoprotein(a) [Lp(a)], an apolipoprotein B (apoB)-containing lipoprotein containing a LDL-like particle, has been reported as a causal risk factor for ASCVD by Mendelian randomization studies, as well as genome-wide association studies (GWAS) [4] [5] [6] . Conversely, the incidence of aortic valve stenosis, based on calcific aortic valvulopathy, where no effective option exists for its progression, is growing among industrialized countries because of aging societies 7, 8) . Moreover, Lp(a) is considered a causal factor in calcific aortic valvulopathy development 9, 10) , making Lp(a) a potential therapeutic target to decrease calcific aortic valvulopathy progression.
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Lp(a) Catabolism
The serum Lp(a) concentration is primarily measured by the rate of apo(a) synthesis, rather than the apo(a) degradation 18, 19) . In addition, the liver has been reported as a major site of apo(a) synthesis, evidenced by studies of patients undergoing therapeutic liver transplantation 20) . The Lp(a) assembly is a two-step process that begins with docking apo(a) to an LDL particle, followed by creating a disulfide bond between the kringle structure and apoB-100; this has been reported to occur at the hepatocyte cell surface, rather than at the endoplasmic reticulum or Golgi 21)
. Conversely, an Lp(a) catabolism pathway remains unclear. The liver is now considered the main organ that clears Lp(a) from the circulation 21) , and some studies using mice models have also suggested the kidneys are contributors 22, 23) . Moreover, kinetic studies in humans have revealed that Lp(a) catabolism was slower than that of LDL, independent of the Lp(a) concentration 24, 25) . Those results suggested that synthesis, rather than catabolism, determines the Lp(a) concentration. Likewise, a plasmapheresis study reported similar results 26) .
Measurements of Lp(a)
Some assays of Lp(a) measurements are reportedly affected by the number of KIV2 repeats 27) . Nevertheless, several studies using methods sensitive to the apo(a) size reported significant correlations between Lp(a) and the ASCVD risk, consistent with those using methods independent of apo(a) size variations. Accordingly, we intend to highlight that the critical question of whose Lp(a) should be measured is more pertinent than how to measure Lp(a).
Pathological and Physiological Roles of Lp(a)
Lp(a) and/or apo(a) have been correlated with prothrombotic properties through interfering with reactions in fibrinolysis regulation, including plasminogen binding to fibrinogen, fibrin, and tetranectin, plasminogen activation by tissue plasminogen activator (t-PA), and augmentation of plasminogen activator inhibitor-1 (PAI-1) activity [28] [29] [30] . Besides those interactions with the fibrinolytic system, other functional properties have been explained as its pathophysiology, including the release of monocyte chemotactic activity from endothelial cells 31) , inhibition of the concentration correlate inversely since smaller isoforms can be made in larger quantities compared to larger isoforms. Both components, LDL-like particle and apo(a), are linked by a single disulfide bond that was localized in one of apo(a) (kringle IV9)'s repeat structures 12) .
Evolution of the Apo(a) Gene
In primates, the apo(a) gene arose from a plasminogen gene ~40 million years ago during evolution 12) . Remarkably, apo(a) is present in humans, nonhuman primates, and Old World monkeys, but not in prosimians, or lower mammals.
Lp(a) Concentration and its Related Factors
The distribution of Lp(a) concentration in most populations is highly positively skewed 13) . Moreover, there are high differences in Lp(a) concentrations across populations; Africans have higher Lp(a) than Caucasian or Asian populations (Fig. 2) 13, 14) . Although the Lp(a) concentration is primarily evaluated by common, single-nucleotide polymorphisms in the LPA gene 15) and is only minimally affected by environmental factors, several other conditions, including renal . Accordingly, Lp(a) could be a causal factor for ASCVD and related diseases, including coronary heart disease, stroke, chronic kidney disease, calcific aortic valvulopathy, heart failure, and peripheral vascular disease 45) . Overall, meta-analyses of epidemiological and genetic studies have demonstrated that elevated Lp(a) levels correlated with an increased risk for ASCVD (Fig. 3) .
Lp(a) and Calcific Aortic Valvulopathy
Calcific aortic valvulopathy, characterized by calcium deposition and thickening of the aortic valve, correlates with aortic valve stenosis. In addition, epidemiological studies have reported several risk factors, including classical coronary risk factors, such as age, male, body mass index, hypertension, diabetes, smoking, renal dysfunction, and LDL cholesterol related to calcific aortic valvulopathy, indicating that treating or preventing those risk factors might decrease the risk of developing aortic valve stenosis 7) . Under these hypotheses, a randomized controlled trial (RCT) was conducted to determine whether further reduction of LDL cholesterol, using ezetimibe on the top of statins, could effectively slow the progression of aortic valve stenosis 46) . Nevertheless, no medical treatment, thus far, has been reported to affect disease progression in patients with calcific aortic valvulopathy. Accordingly, Lp(a) has emerged as a "causal" risk factor based on genetic associations, which could be potential therapeutic targets to prevent calcific aortic valvulopathy plasma catalyzed activation of transforming growth factor-(TGF-) 32) , enhanced proliferation and migration of smooth muscle cells 33) , proliferation of endothelial cells 34) , as well as mesangial cells 35) , and stimulation of the expression of adhesion molecules, such as intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin 36, 37) .
Lp(a) as a Causal Factor for the ASCVD Development: A Standpoint from Genetic Studies
Since the initial results from a GWAS focusing on seven major diseases using 2000 cases and 2000 controls 38) , several GWAS have been conducted to determine novel loci related to various diseases. Of these, correlations between common variants in LPA loci and cardiovascular disease, including coronary artery disease and aortic valve stenosis, have been reported often 39, 40) . Notably, common variants in an LDL receptor markedly correlated with ASCVD, whereas these were not related to calcific aortic valvulopathy outcome 40) . Conversely, common variants in the LPA gene markedly correlate with ASCVD, as well as calcific aortic valvulopathy outcomes as well. Such correlations between genetic variants, resulting in an increase/decrease of a particular biomarker and an outcome, could be considered a proxy of a randomized controlled trial using a particular inhibitor; these are known as "Mendelian randomization studies" 41) . Of note, Mendelian randomization studies could be useful for validating, as well as estimating, the effects/ other groups, have reported Lp(a) levels among FH patients were caused by LDL receptor mutations 14, 17) , resulting in the estimation that LDL-lowering therapies, such as statins, resins, and ezetimibe, could be useful for this purpose. However, studies using those drugs have recurrently reported almost no effect on decreasing Lp(a) levels 52, 53) . Conversely, recently approved proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, which elevate LDL receptor levels by inhibiting its degradation, have been reported to lower Lp(a) levels as much as 30%, with the extent of Lp(a) lowering correlating with the LDL reduction [54] [55] [56] . The mechanism underlying this effect was recently the subject of a comprehensive investigation. Another option could be mipomersen, an apoB inhibitor, which could correlate with the reduction of Lp(a) ~30% 57) ; however, it almost always causes fatty liver since it blocks the secretion of apoB-containing lipoproteins from the liver. Another emerging option could be antisense oligonucleotide (ASO) targeted to apolipoprotein(a). The first-generation drug called IONIS-APO(a)Rx has been reported as a tolerable, potent therapy for decreasing Lp(a) concentrations 54) . Recently, AKCEA-APO(a)-LRx (ISIS 681257), a second-generation, N-acetyl-galactosamine-conjugated, ASO targeted to apolipoprotein(a), was reported to development. Furthermore, elevated Lp(a) levels enhance the calcific aortic valvulopathy progression and, thus, the need for aortic valve replacement (Fig. 4) 47) .
Lp(a) as One of the Residual Factors of Statin Therapies
Several biomarkers are considered so-called "residual risk of statin therapies;" of those, the evidence level obtained from sub-analyses, using RCTs, could be considered higher than those obtained from single-center observational studies. Thus, only a few biomarkers, including triglycerides 48, 49) and Lp(a) 50, 51) , have been explicitly "established" as the residual risk of statin therapies through RCT investigations. Remarkably, both biomarkers have been projected to be causal factors for ASCVD development through Mendelian randomization studies. These facts motivate us to lower those biomarkers, especially among patients with ASCVD under statin therapies.
Lp(a)-Lowering Therapies
For a long time, no satisfactory therapeutic approach existed to lower Lp(a) levels. We, among .
Conclusions and Perspectives
Lp(a), an old molecule, has long been considered a vital causal factor of ASCVD, including calcific aortic valvulopathy. Now, specific therapies reducing Lp(a) quite effectively are projected to become available soon in clinical practice. We would witness whether such emerging novel approaches could tamp down the residual risk, as well as the progression, of calcific aortic valvulopathy.
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